A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736

Translational Lung Cancer Research

Volumn 3, Issue 6, 2014, Pages 408-410

  Lee, Sylvia M ^a   Chow, Laura Q ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84939221583     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2014.11.10     Document Type: Editorial

References (14)

1. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
3. Press release: FDA approves Keytruda for advanced melanoma. 2014. Available online: www.fda.gov/
4. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.
5. Novello S. Clinical activity, safety and biomarkers of PDL1 blockade in non-small cell lung cancer (NSCLC): Additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). European Cancer Congress 2013:abstr 3408.
6. Robert C, Ribas A, Wolchok JD, et al. Anti-programmeddeath- receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17.
7. Segal NH, Antonia SJ, Brahmer JR, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti- PD-L1 antibody. J Clin Oncol 2014;32:abstr 3002.
8. Lutzky J, Antonia SJ, Blake-Haskins A, et al. A Phase 1 Study of MEDI4736, an anti-PD-L1 Antibody, in Patients With Advanced Solid Tumors. J Clin Oncol 2014;32:abstr 3001.
9. Fury M, Bulter M, Ou SH, et al. Clinical activity and safety of MEDI4736, an anti-PD-L1 antibody, in patients with head and neck cancer. 2014 European Society of Medical Oncology (ESMO) Meeting, Madrid, Spain:abstr 988PD.
10. Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 2012;209:201-9.
11. Fairman D, Narwal R, Liang M, et al. Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 2014;32:abstr 2602.
12. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
13. Chen DS, Irving BA, Hodi FS. Molecular pathways: nextgeneration immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012;18:6580-7.
14. Rozali EN, Hato SV, Robinson BW, et al. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012;2012:656340.